hydrocodone plus acetaminophen — Competitive Intelligence Brief

hydrocodone plus acetaminophen (hydrocodone plus acetaminophen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination. Area: Pain Management.

marketed Opioid analgesic combination Mu opioid receptor (hydrocodone); COX inhibitor (acetaminophen) Pain Management Small molecule

Target snapshot

hydrocodone plus acetaminophen (hydrocodone plus acetaminophen) — University of California, Davis. Hydrocodone is an opioid agonist that binds to mu opioid receptors in the central nervous system to reduce pain perception, while acetaminophen inhibits prostaglandin synthesis to provide additional analgesic and antipyretic effects.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
hydrocodone plus acetaminophen TARGET	hydrocodone plus acetaminophen	University of California, Davis	marketed	Opioid analgesic combination	Mu opioid receptor (hydrocodone); COX inhibitor (acetaminophen)
BENZHYDROCODONE	BENZHYDROCODONE		marketed	Opioid analgesic combination; full mu-opioid agonist with non-opioid analgesic	Mu-opioid receptors (primary); delta and kappa opioid receptors (secondary); central nervous system pain pathways	2018-01-01
Codeine paracetamol	Codeine paracetamol	Napp Pharmaceuticals Limited	marketed	Opioid analgesic combination	Opioid receptors (μ, δ, κ); cyclooxygenase (COX-1, COX-2)
dexketoprofen trometamol + tramadol hydrochloride	dexketoprofen trometamol + tramadol hydrochloride	Kavaklıdere Umut Hospital	marketed	NSAID + opioid analgesic combination	COX-1/COX-2 (dexketoprofen); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
Oxycodone and acetaminophen	Oxycodone and acetaminophen	University of Puerto Rico	marketed	Opioid analgesic combination	Mu opioid receptor (oxycodone); cyclooxygenase enzymes (acetaminophen)
Oxycontin/acetominophen	Oxycontin/acetominophen	University of Rochester	marketed	Opioid analgesic combination	Mu opioid receptor (oxycodone); COX inhibitor (acetaminophen)
Nalbuphine and morphine	Nalbuphine and morphine	National Taiwan University Hospital	marketed	Opioid analgesic combination	Opioid receptors (mu, kappa, delta)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination class)

1. VA Office of Research and Development · 3 drugs in this class
2. Rothman Institute Orthopaedics · 2 drugs in this class
3. Labopharm Inc. · 2 drugs in this class
4. University of Rochester · 2 drugs in this class
5. Montefiore Medical Center · 2 drugs in this class
6. Maastricht University Medical Center · 2 drugs in this class
7. Henry Ford Health System · 1 drug in this class
8. Daewon Pharmaceutical Co., Ltd. · 1 drug in this class
9. Albert Einstein College of Medicine · 1 drug in this class
10. Johnson & Johnson Taiwan Ltd · 1 drug in this class